Views on Aurobindo Pharma gets USFDA approval for Azithromycin: Angel Broking

Views of Ms. Sarabjit Kour Nangra (VP Research - Pharma, Angel Broking)

Aurobindo Pharma gets USFDA approval for Azithromycin:

"Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Azithromycin for Injection USP, 500mg /vial (ANDA 203294). Azithromycin for Injection USP, 500mg /vial is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Zithromax® (Azithromycin for Injection) 500mg/vial of Pfizer, Inc. Azithromycin for injection, USP is a macrolide antibacterial drug indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the conditions such as Community-Acquired Pneumonia and Pelvic Inflammatory Disease. We maintain our BUY with a price target of INR 1654.

Shares of AUROBINDO PHARMA LTD. was last trading in BSE at Rs.1395.8 as compared to the previous close of Rs. 1370.4. The total number of shares traded during the day was 86906 in over 3571 trades.

The stock hit an intraday high of Rs. 1399.5 and intraday low of 1370.7. The net turnover during the day was Rs. 120460150.

Source : Equity Bulls

Keywords